Matteo Zignol

12.1k total citations · 1 hit paper
101 papers, 5.2k citations indexed

About

Matteo Zignol is a scholar working on Infectious Diseases, Epidemiology and Surgery. According to data from OpenAlex, Matteo Zignol has authored 101 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 94 papers in Infectious Diseases, 77 papers in Epidemiology and 30 papers in Surgery. Recurrent topics in Matteo Zignol's work include Tuberculosis Research and Epidemiology (94 papers), Pneumocystis jirovecii pneumonia detection and treatment (36 papers) and Mycobacterium research and diagnosis (34 papers). Matteo Zignol is often cited by papers focused on Tuberculosis Research and Epidemiology (94 papers), Pneumocystis jirovecii pneumonia detection and treatment (36 papers) and Mycobacterium research and diagnosis (34 papers). Matteo Zignol collaborates with scholars based in Switzerland, United States and United Kingdom. Matteo Zignol's co-authors include Paul Nunn, Dennis Falzon, Katherine Floyd, Dick van Soolingen, Jaime Bayona, Mario Raviǵlione, A Wright, Keertan Dheda, Paul Jensen and H. Simon Schaaf and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Matteo Zignol

98 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis

2010 782 citations Paul Nunn, Matteo Zignol et al. The Lancet profile →

Peers

Countries citing papers authored by Matteo Zignol

Since Specialization

Citations

This map shows the geographic impact of Matteo Zignol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matteo Zignol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matteo Zignol more than expected).

Fields of papers citing papers by Matteo Zignol

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matteo Zignol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matteo Zignol. The network helps show where Matteo Zignol may publish in the future.

Co-authorship network of co-authors of Matteo Zignol

This figure shows the co-authorship network connecting the top 25 collaborators of Matteo Zignol. A scholar is included among the top collaborators of Matteo Zignol based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matteo Zignol. Matteo Zignol is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	WHO target product profile for TB detection at peripheral settings: 2024 update 2025 ·PLOS Global Public Health ·Mikashmi Kohli, Alexei Korobitsyn, Nazir Ismail, Matteo Zignol, Tereza Kasaeva, Puneet Dewan, Morten Rühwald, (unknown)	0
2	Drug-resistant tuberculosis: a priority pathogen for enhanced public health research and practice 2025 ·Clinical Microbiology Reviews ·H. Manisha Yapa, Emily MacLean, Nicolas A. Menzies, Peter J. Dodd, Anna Dean, Fuad Mirzayev, Samuel G. Schumacher, Linh Nguyen, Matteo Zignol, Greg J. Fox	0
3	Outcomes of people with TB reported to the WHO Global Clinical Platform of COVID-19 2024 ·SHILAP Revista de lepidopterología ·Mathieu Bastard, Dennis Falzon, Silvia Bertagnolio, Renuka Silva, Soe Soe Thwin, (unknown), Jamie Rylance, Janet Dı́az, Matteo Zignol	1
4	The potential impact of novel tuberculosis vaccines on health equity and financial protection in low-income and middle-income countries 2023 ·BMJ Global Health ·Allison Portnoy, Rebecca A. Clark, Chathika K. Weerasuriya, Christinah Mukandavire, Matthew Quaife, Roel Bakker, Inés García Baena, Nebiat Gebreselassie, Matteo Zignol, Mark Jit, Richard G. White, Nicolas A. Menzies	10
5	The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study 2023 ·PLoS Medicine ·Allison Portnoy, Rebecca A. Clark, Matthew Quaife, Chathika K. Weerasuriya, (unknown), Roel Bakker, Arminder Deol, (unknown), Nebiat Gebreselassie, Matteo Zignol, So Yoon Sim, Raymond Hutubessy, Inés García Baena, Nobuyuki Nishikiori, Mark Jit, Richard G. White, Nicolas A. Menzies	22
6	Updating the WHO target product profile for next-generation Mycobacterium tuberculosis drug susceptibility testing at peripheral centres 2023 ·SHILAP Revista de lepidopterología ·Emily MacLean, Paolo Miotto, Licé González-Angulo, (unknown), A Sarah Walker, Martina Casenghi, Camilla Rodrigues, Timothy C. Rodwell, Philip Supply, Emmanuel André, Mikashmi Kohli, Morten Rühwald, Daniela María Cirillo, Nazir Ismail, Matteo Zignol	18
7	The potential impact of novel tuberculosis vaccine introduction on economic growth in low- and middle-income countries: A modeling study 2023 ·PLoS Medicine ·Allison Portnoy, Jean‐Louis Arcand, Rebecca A. Clark, Chathika K. Weerasuriya, Christinah Mukandavire, Roel Bakker, Edith Patouillard, Nebiat Gebreselassie, Matteo Zignol, Mark Jit, Richard G. White, Nicolas A. Menzies	14
8	TB preventive treatment among pregnant women with HIV 2022 ·The International Journal of Tuberculosis and Lung Disease ·(unknown), Yohhei Hamada, (unknown), (unknown), (unknown), Matteo Zignol, Molebogeng X. Rangaka	1
9	25 years of surveillance of drug-resistant tuberculosis: achievements, challenges, and way forward 2022 ·The Lancet Infectious Diseases ·Anna Dean, Olga Tosas Auguet, Philippe Glaziou, Matteo Zignol, Nazir Ismail, Tereza Kasaeva, Katherine Floyd	81
10	TB preventive treatment in high- and intermediate-incidence countries: research needs for scale-up 2021 ·The International Journal of Tuberculosis and Lung Disease ·Olivia Oxlade, Saskia den Boon, Dick Menzies, Dennis Falzon, (unknown), (unknown), Matteo Zignol, Alberto Matteelli	10
11	Characterization of Genomic Variants Associated with Resistance to Bedaquiline and Delamanid in Naive Mycobacterium tuberculosis Clinical Strains 2020 ·Journal of Clinical Microbiology ·Simone Battaglia, Andrea Spitaleri, Andrea Maurizio Cabibbe, Conor J. Meehan, Christian Utpatel, Nazir Ismail, Sabira Tahseen, Alena Skrahina, Natavan Alikhanova, S. M. Mostofa Kamal, A. I. Barbova, Stefan Niemann, Ramona Groenheit, Anna Dean, Matteo Zignol, Leen Rigouts, Daniela María Cirillo	41
12	Advances in clinical trial design: Weaving tomorrow’s TB treatments 2020 ·PLoS Medicine ·Christian Lienhardt, Andrew Nunn, Richard E. Chaisson, Andrew Vernon, Matteo Zignol, Payam Nahid, Éric Delaporte, Tereza Kasaeva	14
13	Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data 2020 ·PLoS Medicine ·Anna Dean, Matteo Zignol, Andrea Maurizio Cabibbe, Dennis Falzon, Philippe Glaziou, Daniela María Cirillo, Claudio U. Köser, Licé González-Angulo, (unknown), Nazir Ismail, Sabira Tahseen, (unknown), Alena Skrahina, Natavan Alikhanova, S. M. Mostofa Kamal, Katherine Floyd	80
14	Use of whole genome sequencing in surveillance of drug resistant tuberculosis 2018 ·Expert Review of Anti-infective Therapy ·Ruth McNerney, Matteo Zignol, Taane G. Clark	17
15	The Burden of Drug-Resistant Tuberculosis in Papua New Guinea: Results of a Large Population-Based Survey 2016 ·PLoS ONE ·(unknown), (unknown), Evelyn Lavu, (unknown), (unknown), Chris Coulter, Julia Ershova, Olga Tosas, Matteo Zignol, (unknown), Tauhid Islam	38
16	Mycobacterium tuberculosisGenotype and Case Notification Rates, Rural Vietnam, 2003–2006 2009 ·Emerging infectious diseases ·Tran N. Buu, Mai Nguyet Thu Huyen, Ngoc‐Lan Nguyen, Hoang Thi Quy, (unknown), Matteo Zignol, Martien W. Borgdorff, Dick van Soolingen, Frank Cobelens	12
17	Informed patient consent for defaulter tracing: should we obtain it? 2009 ·DigitalGeorgetown (Georgetown University Library) ·Akihiro Ohkado, Takehiro Sugiyama, Kyoko Murakami, (unknown), Martien W. Borgdorff, (unknown), (unknown), (unknown), Jintana Ngamvithayapong-Yanai, Pacharee Kantipong, (unknown), (unknown), Diana Weil, Matteo Zignol, Mario Raviǵlione, D A Enarson, Anthony Harries	1
18	Epidemiology of antituberculosis drug resistance 2002–07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance 2009 ·The Lancet ·A Wright, Matteo Zignol, Armand Van Deun, Dennis Falzon, (unknown), (unknown), Sven Hoffner, Francis Drobniewski, Lucía Barrera, Dick van Soolingen, (unknown), (unknown), Kai Man Kam, Satoshi Mitarai, Paul Nunn, Mario Raviǵlione	291
19	Challenges in Estimating the Total Burden of Drug-resistant Tuberculosis 2008 ·American Journal of Respiratory and Critical Care Medicine ·Ted Cohen, Caroline Colijn, A Wright, Matteo Zignol, Alexander S. Pym, Megan Murray	39
20	Global Incidence of Multidrug‐Resistant Tuberculosis 2006 ·The Journal of Infectious Diseases ·Matteo Zignol, Mehran Hosseini, A Wright, (unknown), Paul Nunn, Catherine Watt, Brian Williams, Christopher Dye	402

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact